Latest Period
Q1 2026
Security Snapshot
Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB) Institutional Ownership
CUSIP: 746964105
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
53
Shares (Excl. Options)
9,428,888
Price
$6.42
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- QTTB on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 9,428,888
- Total 13F value
- $60,617,009
- Portfolio coverage rank
- 0%
- Share change
- +1,349,287
- Value change
- +$9,025,150
- Number of holders
- 53
- Shares outstanding
- 23,698,939
- SEC-reported price per share
- $10.31
- Insider filing price
- $10.31
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- QTTB - Q32 Bio Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 746964105.
- 53 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 51 to 53 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $26,659,216 to $60,617,009.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 53 institutions filings for Q1 2026.
Security key
746964105
Latest holder period
Q1 2026
13F holders
53
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
QTTB full holder history
Q32 Bio Inc. SEC filings
Q32 Bio Inc. company facts
Q32 Bio Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 746964105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
QTTB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 17% | +32% | $22,703,928 | +$10,312,500 | 4,127,987 | +83% | ORBIMED ADVISORS LLC | 28 May 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 10% | $13,021,382 | 2,367,524 | BVF PARTNERS L P/IL | 28 May 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.8% | $12,828,514 | 2,332,457 | RA Capital Management, L.P. | 28 May 2026 | |||
| Sirenia Capital Management LP | 9.9% | $12,138,117 | 2,057,308 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Opaleye Management Inc. | 8.6% | -0.67% | $7,411,745 | 1,256,228 | 0% | Opaleye Management Inc. | 31 Mar 2026 | |
| Point72 Asset Management, L.P. | 5.7% | -42% | $5,656,731 | -$6,481,386 | 958,768 | -53% | Point72 Asset Management, L.P. | 31 Mar 2026 |
| Atlas Venture Fund X, L.P. | 3.6% | $4,753,436 | 864,261 | Atlas Venture Fund X, L.P. | 26 May 2026 | |||
| PFIZER INC | 2.3% | $994,442 | 277,777 | Pfizer Inc. (IRS Identification No.: 13-5315170) | 31 Dec 2024 | |||
| BRISTOL MYERS SQUIBB CO | 1.6% | $312,381 | 200,244 | BRISTOL MYERS SQUIBB CO | 31 Dec 2024 |
As of 31 Mar 2026, 53 institutional investors reported holding 9,428,888 shares of Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB). This represents 40% of the company’s total 23,698,939 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
39%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 9.5% | 2,252,987 | 0% | 0.33% | $14,464,177 |
| Atlas Venture Life Science Advisors, LLC | 8.8% | 2,092,106 | 0% | 1.7% | $13,431,321 |
| Opaleye Management Inc. | 5.3% | 1,256,228 | +489% | 1.1% | $8,064,984 |
| Carlyle Group Inc. | 4.7% | 1,102,741 | 0% | 0.07% | $7,079,597 |
| ARCH Venture Management, LLC | 1.4% | 320,482 | 0% | 0.3% | $2,057,494 |
| ACORN CAPITAL ADVISORS, LLC | 1.3% | 315,052 | -36% | 0.57% | $2,022,634 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3% | 306,401 | 0% | 0% | $1,967,094 |
| MACKENZIE FINANCIAL CORP | 1% | 246,304 | 0% | $1,581,272 | |
| Sanofi | 1% | 244,083 | 0% | 0.47% | $1,567,013 |
| RENAISSANCE TECHNOLOGIES LLC | 0.87% | 206,915 | +108% | 0% | $1,328,394 |
| ACADIAN ASSET MANAGEMENT LLC | 0.73% | 172,586 | +257% | 0% | $1,106,000 |
| MONIMUS CAPITAL MANAGEMENT, LP | 0.57% | 134,310 | 0.24% | $862,270 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.5% | 118,152 | +11% | 0% | $758,740 |
| Pfizer Inc | 0.43% | 101,618 | -63% | 0.31% | $736,731 |
| BlackRock, Inc. | 0.36% | 86,147 | +44% | 0% | $553,063 |
| JANE STREET GROUP, LLC | 0.28% | 65,599 | +159% | 0% | $421,145 |
| MARSHALL WACE, LLP | 0.22% | 52,440 | 0% | $336,664 | |
| VANGUARD FIDUCIARY TRUST CO | 0.21% | 49,995 | 0% | 0% | $320,968 |
| TWO SIGMA INVESTMENTS, LP | 0.18% | 42,346 | -9.6% | 0% | $271,861 |
| STATE STREET CORP | 0.18% | 41,514 | +95% | 0% | $266,520 |
| Cambridge Investment Research Advisors, Inc. | 0.15% | 35,025 | 0% | $225,000 | |
| ADAR1 Capital Management, LLC | 0.15% | 35,000 | +75% | 0.01% | $224,700 |
| Affinity Asset Advisors, LLC | 0.12% | 27,777 | 0% | 0.01% | $178,328 |
| NORTHERN TRUST CORP | 0.11% | 25,033 | 0% | 0% | $160,712 |
| Cetera Investment Advisers | 0.09% | 20,695 | 0% | $132,862 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Latest
Q1 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 9,428,888 | $60,617,009 | +$9,025,150 | $6.42 | 53 |
| 2025 Q4 | 8,043,846 | $26,659,216 | -$1,063,038 | $3.32 | 51 |
| 2025 Q3 | 8,428,600 | $16,632,224 | -$986,951 | $1.98 | 52 |
| 2025 Q2 | 8,978,370 | $13,355,302 | -$657,201 | $1.49 | 59 |
| 2025 Q1 | 9,406,123 | $15,511,257 | -$5,227,234 | $1.65 | 71 |
| 2024 Q4 | 10,994,953 | $37,808,803 | -$51,251,129 | $3.44 | 88 |
| 2024 Q3 | 9,108,413 | $405,845,227 | +$55,628,540 | $44.62 | 71 |
| 2024 Q2 | 8,065,328 | $144,178,979 | +$11,388,677 | $17.95 | 54 |
| 2024 Q1 | 7,430,290 | $125,894,701 | +$125,894,701 | $17.04 | 38 |